Johnson & Johnson reports promising early results for targeted bladder cancer therapy
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
The trial will enroll up to 42 patients in Finland across four cohorts
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Subscribe To Our Newsletter & Stay Updated